Skip to main content
TipRanks
Go Ultimate75% OFF

Motus Gi Holdings (MOTS) AI Stock Analysis

524 Followers
MOTS

Motus Gi Holdings

(Other OTC:MOTS)

Select Model
Rating:38Underperform
Action:N/A
Date:01/03/25

Motus Gi Holdings faces significant financial instability with declining revenues, consistent net losses, and negative cash flows. The absence of technical analysis data and a negative P/E ratio suggest continued challenges in market performance and profitability. The lack of earnings call guidance exacerbates uncertainty, leading to a low overall stock score.

Positive Factors
Innovative Product OfferingThe Pure-Vu System enhances the efficacy of colonoscopies, potentially reducing the need for repeat procedures. This innovation can drive adoption in hospitals and clinics, supporting long-term revenue growth as the product addresses a critical need in gastrointestinal endoscopy.
Negative Factors
Declining Revenue TrendA declining revenue trend poses a significant challenge, indicating reduced market demand or competitive pressures. This trend can strain financial resources and limit growth opportunities, impacting the company's ability to invest in new initiatives or expand its market presence.

Motus Gi Holdings (MOTS) vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%MOTS0.00%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1,278
Dividend Yield
―
Average Volume (3M)
1,005
Price to Earnings (P/E)
0.0
Beta (1Y)
413.08
Revenue Growth
―
EPS Growth
―
Country
US
Employees
15
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Motus Gi Holdings Business Overview & Revenue Model

Company Description

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper g...

How the Company Makes Money

Motus GI Holdings generates revenue primarily through the sale and distribution of its Pure-Vu System and related accessories. The company targets hospitals and clinics that perform colonoscopies, promoting the Pure-Vu System as a means to optimize p...

Motus Gi Holdings Risk Analysis

Motus Gi Holdings disclosed 61 risk factors in its most recent earnings report. Motus Gi Holdings reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.If our shares of common stock become subject to the penny stock rules, it will become more difficult to trade our shares of common stock.Q1, 2024

Motus Gi Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

MOTS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AEMDAEMD44Neutral$8.15M-0.47-141.22%――90.69%
BMRABMRA42Neutral$5.68M-0.79-142.81%―-11.20%-6.64%
PAVMPAVM42Neutral$12.07M-0.16-58.07%―410.34%-185.92%
MOTSMOTS38Underperform$1,2780.00-454.34%―――

* Healthcare Sector Average

Performance Comparison

-50%0%MOTSBMRAAEMDPAVMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MOTS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MOTSMotus Gi Holdings0.010.000.00%
BMRABiomerica Inc1.24-0.95-43.35%
AEMDAethlon5.08-13.77-73.05%
PAVMPavmed1.51-10.09-86.98%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 03, 2025